|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Respiratory Unit (Drs. Wood, Robson, Innes, and Greening), Western General Hospital, Edinburgh, and Osler Chest Unit (Dr. Ho), Churchill Hospital, Oxford, United Kingdom.
Correspondence to: Ling-Pei Ho, MD, Osler Chest Unit, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom
| Abstract |
|---|
|
|
|---|
Setting: Specialist respiratory unit in a university teaching hospital.
Patients: Twenty-eight asthmatics (mean FEV1, 85.7%) receiving short-acting inhaled bronchodilators and a range of inhaled steroids (0 to 4,000 µg/d).
Interventions: Subjects were studied on two occasions, 5 to 7 days apart, between September and March.
Measurements and results: On the first day, FEV1, exhaled NO, and histamine challenge were performed. On the second day, exhaled NO, total IgE, and skin-prick testing to six common allergens were conducted. Exhaled NO was measured with the single exhalation method. We found exhaled NO levels to correlate positively with total IgE (r = 0.43, p = 0.02) and number of positive skin-prick tests (p = 0.002). By contrast, there was no significant correlation between exhaled NO and FEV1 or the provocative concentration causing a 20% fall in FEV1. Subanalyses of steroid-treated and steroid-naive patients in this group revealed the same findings.
Conclusion: Exhaled NO levels in asthmatics correlate more closely with atopy than with bronchial hyperreactivity and lung function.
Key Words: asthma atopy exhaled nitric oxide
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
Study Protocol
Asthmatic subjects were asked to attend on two occasions, 5 to 7
days apart. On the first day, clinical history, exhaled NO,
FEV1, and PC20 on histamine
challenge were measured. On the second visit, exhaled NO was measured
again, venipuncture was performed for total plasma IgE, and skin-prick
testing was conducted. Exhaled NO levels were measured before
spirometric maneuvers and histamine challenge.
Exhaled NO levels obtained on respective days of measurement were compared with measures of atopy (histamine-equivalent wheal [HEW] as described below, total IgE, and number of positive skin-prick tests), FEV1, and PC20.
Normal subjects were asked to attend on 1 day when exhaled NO and FEV1 were measured. Since NO levels are known to be affected by seasonal exposure to airborne allergens,12 we conducted the study between September and March to eliminate this possible confounding factor. The study was approved by the regional ethics committee (Lothian Health Ethics Committee).
Exhaled NO Measurement
Exhaled NO was measured using a chemiluminescence analyzer (LR
2000; Logan Research Ltd; Kent, UK). The analyzer provides online
continuous measurement of NO in a single exhalation with a detection
limit of 0.3 parts per billion (ppb) of NO. The analyzer was calibrated
daily with NO/N2 calibration gas containing 103
ppb of NO (BOC; Guildford, UK). All subjects exhaled at a constant rate
(15 L/min), maintaining a constant mouth pressure of 5 cm
H2O by observing a visual display of this
pressure. As previously described, the 95% confidence interval for
each measurement is ± 1.72 ppb.13
The subjects NO
level was recorded as the mean of three consecutive readings taken at
the plateau of the exhalation profile. The method conformed optimally
with European Respiratory Society guidelines on exhaled NO
measurements.14
Skin-Prick Testing
Cutaneous response to allergens was assessed by skin-prick
testing on the forearm to the following allergens (BioDiagnostics;
Worcestershire, UK): cat and dog dander, house dust mite
(Dermatophagoides pteronyssinus), grass pollen, tree pollen,
and Aspergillus fumigatus, compared with a saline solution
negative control and a histamine positive control. After 15 min, the
wheal diameter was measured against the positive control. All
measurements equal to or greater than the positive control were
considered as positive responses. Histamine equivalent wheal (HEW) was
calculated as the maximum diameter of the allergen wheal minus the
maximum diameter of the histamine control wheal.15
All the
HEWs on one subject were then summed to give a numerical representation
of cutaneous allergic response for that subject.
Total IgE
Circulating total IgE in the plasma was measured using a
fluorometric enzyme immunoassay (UniCAP; Pharmacia & Upjohn; Milton
Keynes, UK). The normal value with this method is < 144 kU/L.
Histamine Challenge
Histamine challenge was performed using a tidal breathing
method. Histamine (Tayside Pharmaceuticals; Dundee, UK) was delivered
using a breath-activated dosimeter in doubling concentration from 0.25
mg/mL until at least a 20% decrease in FEV1,
compared with baseline (0.9% saline solution inhalation), was
recorded. PC20 was determined by linear
interpolation between the last two data points on the log
concentration-response curve.
Statistical Analysis
Where data were normally distributed with constant variance,
correlations were measured using Pearsons moment product correlation.
Otherwise, the Spearman rank sum correlation was used. For comparisons
of exhaled NO between groups with increasing number of positive
skin-prick tests, one-way analysis of variance on ranks (Kruskal-Wallis
method) was used, and Dunns method was used subsequently for pairwise
comparisons. Comparison of exhaled NO between normal and asthmatic
groups was performed using the Mann-Whitney test inasmuch as exhaled NO
in both groups followed a nonparametric distribution. Statistical
significance was assumed at p < 0.05, and data are expressed as mean
± SD.
| Results |
|---|
|
|
|---|
|
Exhaled NO and Atopic Measurements
Exhaled NO within the asthmatic population was found to correlate
positively with HEW (r = 0.73; p < 0.001; Spearman rank
correlation; Fig 1
,
right). There was a highly significant difference in exhaled
NO between those subjects with no positive skin-prick test and those
with one to two and three to four positive tests (p = 0.002;
Kruskal-Wallis analysis of variance on ranks; Fig 1 , left).
|
|
Subanalysis of Steroid-Naïve Asthmatics and Those Receiving
Inhaled Steroids
We subanalyzed the data by assessing the patients who were
not receiving inhaled steroids (n = 11) and those who were receiving
inhaled steroids (n = 17). The results were similar to the group as a
whole (Table 2
).
|
| Discussion |
|---|
|
|
|---|
During the preparation of this article, a similar study was published by Simpson et al,19 showing almost identical results. Our study extends their findings by demonstrating that the relationship between exhaled NO and atopy holds even for asthmatics receiving inhaled steroids. Because iNOS is steroid sensitive, the explanation for this observation is unclear. Could steroid-induced modification in exhaled NO correspond to steroid-induced reduction in atopic activity? This is unlikely because although exhaled NO would be lowered by inhaled steroid use, it would not affect mast cell activity at sites other than the area of application20 and therefore should not influence skin-prick positivity and total IgE count. Further, we found no correlation between steroid dose and severity of atopy. Thus, it would seem that the relationship between exhaled NO and atopy shows a positive correlation, which is not the case with inhaled steroids and exhaled NO. This may be because the effect of atopy is much stronger than that of inhaled steroids and therefore overrides that of inhaled steroids. The suggestion could be that allergy-mediated production of NO, eg, from eosinophils or T helper-2 activation may be greater than that from neutrophils and inflamed epithelial cells and not as responsive to steroid treatment. However, it could also be hypothesized that iNOS expression in atopic asthmatics is less responsive to inhaled steroids, and therefore they continue to produce high levels of NO in the airways.
Putting our findings and those from the other studies in context of data on sputum and peripheral eosinophilia, it can be suggested that increased exhaled NO levels reflect a specific type of inflammation, that of T helper-2driven inflammatory response rather than nonspecific airway inflammation. Increasing evidence suggests that airway inflammation in atopic asthma is associated with a T helper-2 cytokine profile, characterized by interleukin-4 and interleukin-5 production.21 22 These cytokines promote switching of B-cell isotypes to IgE production and activation of eosinophils, respectively. Interleukin-4 also appears to prolong the expression of iNOS in airway epithelium, providing a possible explanation for increased production of NO from the airways.23
The idea that increased levels of exhaled NO are related to a specific type of airway inflammation would be in keeping with lack of increase in other airway inflammatory disorders, such as ARDS,24 cystic fibrosis,13 and COPD,25 26 in which there is excess neutrophilic inflammation. This is somewhat surprising, as neutrophils are thought to produce far greater amounts of NO than the epithelium, endothelium, or eosinophils.27 The lack of increase in these conditions may be attributed to the substantial release of other reactive species, such as superoxide anion, which then chemically remove NO from detection in the exhaled gas.28 Asthma may therefore be the unique inflammatory airway condition that demonstrates increased exhaled NO levels by virtue of its underlying atopic nature. This could also explain why some untreated asthmatics do not have increased NO levels, because not all asthma has an atopic basis.
In conclusion, our study showed that within an asthmatic population, exhaled NO levels correlated with atopy in both steroid-treated and steroid-naïve subgroups. This suggests that in asthmatics, increased NO production may be predominantly a feature of atopy.
| Footnotes |
|---|
Supported by the Medical Research Council (United Kingdom) and Nimar Charitable Trust. The nitric oxide analyzer was purchased with an educational grant from Glaxo Wellcome. Dr. Ho was supported by Medical Research Council Program grant G9313618.
Received for publication February 3, 2000. Accepted for publication May 18, 2000.
| References |
|---|
|
|
|---|
and IL4 stimulate prolonged expression of iNOS in human airway epithelium through synthesis of soluble mediator. J Clin Invest 100,829-838[ISI][Medline]
This article has been cited by other articles:
![]() |
K. G. Lim and C. Mottram The Use of Fraction of Exhaled Nitric Oxide in Pulmonary Practice Chest, May 1, 2008; 133(5): 1232 - 1242. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kostikas, A. I. Papaioannou, K. Tanou, A. Koutsokera, M. Papala, and K. I. Gourgoulianis Portable Exhaled Nitric Oxide as a Screening Tool for Asthma in Young Adults During Pollen Season Chest, April 1, 2008; 133(4): 906 - 913. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Miedinger, P. N. Chhajed, M. Tamm, D. Stolz, C. Surber, and J. D. Leuppi Diagnostic Tests for Asthma in Firefighters Chest, June 1, 2007; 131(6): 1760 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-C. Olin, A. Rosengren, D. S. Thelle, L. Lissner, B. Bake, and K. Toren Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest, November 1, 2006; 130(5): 1319 - 1325. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Franklin, S. M. Stick, P. N. Le Souef, J. G. Ayres, and S. W. Turner Measuring Exhaled Nitric Oxide Levels in Adults: The Importance of Atopy and Airway Responsiveness Chest, November 1, 2004; 126(5): 1540 - 1545. [Abstract] [Full Text] [PDF] |
||||
![]() |
P J Franklin, S W Turner, P N Le Souef, and S M Stick Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children Thorax, December 1, 2003; 58(12): 1048 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Varner The Increase in Allergic Respiratory Diseases : Survival of the Fittest? Chest, April 1, 2002; 121(4): 1308 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Stick Exhaled Nitric Oxide in Difficult Childhood Asthma . More Light or Still Chasing Shadows? Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): 1335 - 1336. [Full Text] [PDF] |
||||
![]() |
L. Lehtimaki, H. Kankaanranta, S. Saarelainen, V. Turjanmaa, and E. Moilanen Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma Eur. Respir. J., October 1, 2001; 18(4): 635 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. KHARITONOV and P. J. BARNES Exhaled Markers of Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1693 - 1722. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |